Litigation Details for Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2018)
Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2018)
| Docket | ⤷ Start Trial | Date Filed | 2018-05-08 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | |
| Jury Demand | Referred To | ||
| Patents | 9,724,310; 9,730,900 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC
Details for Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-05-08 | 112 | Opinion - Memorandum Opinion | infringement of U.S. Patent Nos. 9,730,900 (the "' 900 Patent"), 9,724,310 (the '"…310 Patent"), and 9,833 ,419 (the '" 419 Patent") (collectively, "patents-in-…-suit" or "asserted patents"). (D.I. 83 at 3) The patents-in-suit relate "to transdermal…; It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent "specification | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
